Abbott's proclaim™ xr spinal cord stimulation system now offers expanded mri compatibility in u.s.

Abbott park, ill., jan. 4, 2022 /prnewswire/ -- abbott (nyse: abt) announced today that the u.s. food and drug administration (fda) has approved new expanded magnetic resonance imaging (mri) compatibility for its proclaim™ xr spinal cord stimulation (scs) system with octrode™ leads.
ABT Ratings Summary
ABT Quant Ranking